RemeGen CoREGMF -6.23%41 Days Payable is 140.91 as of Dec. 2025, which is 47% below its 10-year median of 265.79. GuruFocus rates REGMF with a GF Score™ of 41/100 and a GF Value™ of $25.65 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 702 Biotechnology companies, RemeGen Co ranks better than 70.66% on this metric.
RemeGen Co's average Accounts Payable for the
three
months ended in Dec. 2025 was $34.0 Mil. RemeGen Co's Cost of Goods Sold for the
three
months ended in Dec. 2025 was $22.0 Mil.
Hence, RemeGen Co's Days Payable for the
three
months ended in Dec. 2025 was 140.91.
The historical rank and industry rank for RemeGen Co's Days Payable or its related term are showing as below:
REGMF'
s Days Payable Range Over the Past 10 Years
Min: 162.37 Med: 265.79 Max: 684.28
Current: 302.25
During the past 8 years, RemeGen Co's highest Days Payable was 684.28. The lowest was 162.37. And the median was 265.79.
REGMF's Days Payable is ranked better than 70.66% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs REGMF: 302.25
RemeGen Co's Days Payable
declined
from Sep. 2024 (190.25) to Dec. 2025 (140.91).
It may suggest that RemeGen Coaccelerated paying its suppliers.
RemeGen Co Days Payable Related Terms
RemeGen Co Days Payable Historical Data
* Premium members only.
The historical data trend for RemeGen Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
REGMF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, RemeGen Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's Days Payable distribution charts can be found below:
* The bar in red indicates where RemeGen Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
RemeGen Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co (REGMF) has a Days Payable of 140.91 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on RemeGen Co and its competitors. This is 47% below median its historical median of 265.79. Over the past decade, RemeGen Co's Days Payable has ranged from 162.37 to 684.28. According to the industry distribution chart, RemeGen Co ranks #206 out of 702 companies in the Biotechnology industry, placing it in the top 29.3%.
Is RemeGen Co's Days Payable too high?
RemeGen Co's current Days Payable of 140.91 is 47% below median its 10-year median of 265.79. Over the past 10 years, this metric has ranged from a low of 162.37 to a high of 684.28. The Biotechnology industry median Days Payable is 113.10. RemeGen Co's value of 140.91 is 24.6% above this industry median. Based on the distribution chart, RemeGen Co ranks #206 out of 702 companies in the Biotechnology industry, which is above the industry midpoint. Overall, RemeGen Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #206 out of 702 companies for Days Payable. This puts RemeGen Co in the upper half of its industry. The industry median Days Payable is 113.10. RemeGen Co's value of 140.91 is 24.6% above this benchmark. Historically, RemeGen Co's own Days Payable has ranged from 162.37 to 684.28 over the past decade. While the company's 10-year median is 265.79 vs. the industry median of 113.10, RemeGen Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RemeGen Co's current Days Payable of 140.91 is 24.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on RemeGen Co and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RemeGen Co's current Days Payable is 140.91, which is 47% below median its own 10-year median of 265.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (REGMF) is currently considered Possible Value Trap. The stock's GF Value™ is $25.65, compared to a current price of $12.05 — trading 53% below its estimated fair value. The current Days Payable is 140.91, which is 47% below median its 10-year median of 265.79 and 24.6% above the Biotechnology industry median of 113.10. RemeGen Co's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For RemeGen Co (REGMF), the current Days Payable is 140.91 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RemeGen Co (REGMF) Overvalued in 2026?
Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued.
The current stock price of $12.05 is trading 53% below its estimated GF Value™ of $25.65.
GuruFocus considers RemeGen Co to be Possible Value Trap.
Key valuation signals for REGMF:
Days Payable: 140.91 (47% below median its 10-year median of 265.79)
GF Value™: $25.65 vs. price of $12.05 (53% below fair value)
Industry Position: 24.6% above the Biotechnology median (#206 of 702)
No single metric tells the full story. See the REGMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
41GF Score
Get the complete analysis for REGMF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REGMF has been successfully added to your 
